Ind-Swift surges on talk of atorvastatin API supply deal with Ranbaxy
This article was originally published in Scrip
Executive Summary
Shares of Ind-Swift Laboratories were on a roll on Indian bourses on 14 September following reports that the firm was in discussions to supply atorvastatin active pharmaceutical ingredient (API) to Ranbaxy for the latter's cut-price generic version of Pfizer's Lipitor. A US launch of Ranbaxy's product is expected at the end of November this year.